Low-Dose Ketamine and Cannabis: What Patients Should Know

Low dose ketamine and cannabis should generally be kept separate around a treatment session. Both can affect perception, anxiety, heart rate, blood pressure, attention, and memory. Direct research on their combined use in ketamine treatment is limited, so the safest plan is to tell your prescriber exactly what cannabis products you use and follow that clinician's instructions about holding them before and after treatment.

Cannabis use does not automatically rule out ketamine therapy. It does mean that treatment planning, monitoring, and symptom assessments may need extra care.

Why cannabis can complicate ketamine treatment

The main concern is overlapping short-term effects. THC, the primary psychoactive component of cannabis, can alter perception and increase anxiety or panic in some people, particularly at higher doses. Ketamine can also cause dose-dependent dissociation through NMDA receptor antagonism. Taking them close together may make it harder to predict how a person will feel during or after treatment.

Both substances can also affect cardiovascular measures and thinking. THC may increase heart rate, while ketamine can raise heart rate and blood pressure. Both can temporarily impair attention, working memory, and decision-making. That overlap can complicate safety monitoring and may extend the period when a patient should avoid driving, work requiring alertness, or other risky activities.

According to the National Institute on Drug Abuse, inhaled cannabis effects can last 2-4 hours, although residual cognitive and physiological effects may last longer. Dose, THC concentration, route of use, individual tolerance, and other medications all affect the experience.

What is known, and what remains unclear

There are no published randomized controlled trials specifically designed to test the cannabis-ketamine interaction in clinical ketamine therapy. The available discussion is based on pharmacology, preclinical research, case reports, and clinical observation. Those sources can identify plausible risks, but they cannot establish that cannabis changes ketamine response rates or that one specific waiting period is right for every patient.

Ketamine's pharmacology and metabolism are described in a review by Zanos and colleagues in Pharmacological Reviews. The endocannabinoid system also interacts with glutamate signaling, which is relevant because glutamate pathways are central to ketamine's effects. As described by Katona and Freund, endocannabinoid signaling can regulate synaptic transmission. It remains unclear whether THC or CBD meaningfully changes ketamine's therapeutic effects in people.

CBD differs from THC because it is not typically intoxicating in the same way. CBD may inhibit enzymes involved in drug metabolism, including CYP3A4 and CYP2C19. That creates a theoretical possibility of altered ketamine clearance, but this interaction has not been adequately studied in ketamine therapy. Bring CBD oils, gummies, capsules, and combination products to your prescriber's attention, even if they are sold as wellness products.

Practical timing guidance to discuss with your provider

A conservative clinical approach is to avoid inhaled cannabis for at least 24 hours before a ketamine session and to ask about a longer interval for oral cannabis products. Edibles and tinctures have slower absorption and may have longer-lasting effects than inhaled products. For daily medical cannabis use, a treatment-day hold may or may not be appropriate, so the prescribing clinician should guide that decision.

After ketamine, avoid cannabis for at least 12-24 hours unless your treatment team gives different instructions. A 24-hour interval may be particularly prudent after an IV infusion because peak ketamine concentrations are higher. Patients following an at-home sublingual or oral protocol should not combine cannabis and ketamine on the same day without explicit clinical direction.

These are cautious clinical recommendations, not proven universal rules. The protocol may change based on your ketamine route, dose, cardiovascular history, psychiatric history, other medications, and the cannabis product involved. See our guide to ketamine drug interactions and our overview of ketamine and alcohol safety risks for related interaction questions.

Why accurate assessment matters

Cannabis taken close to treatment can make outcome tracking less reliable. It may temporarily change mood, anxiety, pain, sleep, and concentration. If those changes overlap with a PHQ-9, MADRS, or other symptom check, the score may not reflect your usual baseline.

It can also make side effects harder to interpret. Anxiety, derealization, impaired concentration, nausea, tachycardia, and poor sleep can have more than one possible cause. A simple record of cannabis use, including timing and route, gives your clinician better context for dose and scheduling decisions. Our article on ketamine safety and side effects explains the monitoring questions patients can expect.

When to raise cannabis use promptly

Contact the clinician managing your ketamine care before the next session if cannabis use has led to panic, severe dissociation, chest symptoms, fainting, confusion, or difficulty following the treatment plan. Also raise the issue if you use cannabis heavily every day, feel unable to reduce use around sessions, or think your use is worsening anxiety, motivation, or memory.

Cannabis use disorder can add complexity because it may be difficult to follow an agreed hold period and because cannabis-related symptoms can overlap with mood symptoms. Screening and nonjudgmental discussion can help a clinician decide whether ketamine scheduling, additional support, or substance-use treatment should be considered. The National Academies report on the health effects of cannabis and cannabinoids provides broader evidence context for patients and clinicians.